Retender radar: UK public contracts ending soon
Every contract on Find a Tender with a published end date in the future, one row per contract (lot). A contract ending is a procurement starting — unless the buyer uses a published extension option, which the row shows. Frameworks and DPS are marked: what ends there is the vehicle, not one supplier’s contract.
When contracts end · Medical equipments, pharmaceuticals i
When contracts here run out.
Published contracts by their end date. No end date, not counted.
A likely retender, not a certain one.
i
When contracts here run out.
Published contracts by their end date. No end date, not counted.
A likely retender, not a certain one.
902 contracts end within 24 months, 1,006 in total · £90m published GBP value, exc. VAT, in the next 12 months (framework ceilings included, not a spend forecast).
By sector, next 12 months i
When contracts here run out.
Published contracts by their end date. No end date, not counted.
A likely retender, not a certain one.
i
When contracts here run out.
Published contracts by their end date. No end date, not counted.
A likely retender, not a certain one.
CPV division of the procedure; a contract with several divisions counts in each.
85Health and social work services1,17133Medical equipments, pharmaceuticals59179Business services: law, marketing, consulting48172IT services: consulting, software, internet18580Education and training services17860Transport services (except waste transport)17550Repair and maintenance services16715Food, drink, tobacco164
Contracts ending in the next 12 months
Showing 351–400
- Ends · in 200 daysFramework re-let
Factor XIII - Recombinant
NHS England · NHS & health · Nationwide (UK)
Incumbent: Novo Nordisk
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Standard Half-life Recombinant Factor VIII
NHS England · NHS & health · Nationwide (UK)
Incumbent: Takeda UK Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Von willebrands factor / Factor VIII
NHS England · NHS & health · Nationwide (UK)
Incumbent: Octapharma Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Von willebrands factor / Factor VIII
NHS England · NHS & health · Nationwide (UK)
Incumbent: CSL BEHRING UK LIMITED
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Von willebrands factor - Plasma Derived
NHS England · NHS & health · Nationwide (UK)
Incumbent: LFB
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Von willebrands factor - Recombinant
NHS England · NHS & health · Nationwide (UK)
Incumbent: Takeda UK Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Fibrinogen Concentrate
NHS England · NHS & health · Nationwide (UK)
Incumbent: LFB
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Fibrinogen Concentrate
NHS England · NHS & health · Nationwide (UK)
Incumbent: Octapharma Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Fibrinogen Concentrate
NHS England · NHS & health · Nationwide (UK)
Incumbent: CSL BEHRING UK LIMITED
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Prothrombin Complex dried
NHS England · NHS & health · Nationwide (UK)
Incumbent: Takeda UK Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Prothrombin Complex dried
NHS England · NHS & health · Nationwide (UK)
Incumbent: Octapharma Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Prothrombin Complex dried
NHS England · NHS & health · Nationwide (UK)
Incumbent: CSL BEHRING UK LIMITED
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Standard Half-life Recombinant Factor VIII
NHS England · NHS & health · Nationwide (UK)
Incumbent: Octapharma Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Protein C Concentrate
NHS England · NHS & health · Nationwide (UK)
Incumbent: Takeda UK Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Fresh Frozen Plasma (all blood groups)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Octapharma Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Enhanced Half-life Recombinant Factor VIII
NHS England · NHS & health · Nationwide (UK)
Incumbent: Novo Nordisk
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Enhanced Half-life Recombinant Factor VIII
NHS England · NHS & health · Nationwide (UK)
Incumbent: Sobi (Swedish Orphan Biovitrum Ltd)
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Emicizumab
NHS England · NHS & health · Nationwide (UK)
Incumbent: Roche Products Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
Eftrenonacog alfa (rFIX EHL)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Sobi (Swedish Orphan Biovitrum Ltd)
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
albutrepenonacog alfa (rFIX EHL)
NHS England · NHS & health · Nationwide (UK)
Incumbent: CSL BEHRING UK LIMITED
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 daysFramework re-let
nonacog beta pegol (rFIX EHL)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Novo Nordisk
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-043b0e
- Ends · in 200 days
Varicella-zoster immunoglobulin (VZIG) 2025
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · NHS & health · Nationwide (UK)
Incumbent: BIO PRODUCTS LABORATORY LIMITED
- Contract value
- £1
- Annual run-rate
- —start date not published
- Term
- Ends 30 Apr 2027 · start not published
- Reference
ocds-h6vhtk-047b9e
- Ends · in 200 days
Varicella-zoster immunoglobulin (VZIG) 2025
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · NHS & health · Nationwide (UK)
Incumbent: BIO PRODUCTS LABORATORY LIMITED
- Contract value
- £1
- Annual run-rate
- £1value ÷ published term
- Term
- 1 May 2025 → 30 Apr 2027 · 1.9 yrs
- Reference
ocds-h6vhtk-047b9e
- Ends · in 200 days
Varicella-zoster immunoglobulin (VZIG) 2025
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · NHS & health · Nationwide (UK)
Incumbent: Grifols UK
- Contract value
- £1
- Annual run-rate
- £1value ÷ published term
- Term
- 1 May 2025 → 30 Apr 2027 · 1.9 yrs
- Reference
ocds-h6vhtk-047b9e
- Ends · in 231 daysFramework re-letExtension option · up to 31 May 2029Panel · 5 suppliers
Lot 2 - CM/PHS/25/5728/02
NHS England · Central government · Nationwide (UK), North East England, North West England, Yorkshire and the Humber, East Midlands, West Midlands
Panel: Bayer Plc, Biosimilar Collaborations Ireland Limited, Celltrion Healthcare Uk Ltd +2 more
- Contract value
- £783mceiling for the whole framework
- Annual run-rate
- —panel, not one supplier
- Term
- 1 Dec 2025 → 31 May 2027 · 1.4 yrs · up to 31 May 2029 with extensions
- Reference
ocds-h6vhtk-055064
- Ends · in 231 daysFramework re-letExtension option · up to 31 May 2029Panel · 14 suppliers
Lot 1 - CM/PHS/25/5728/01
NHS England · Central government · Nationwide (UK), North East England, North West England, Yorkshire and the Humber, East Midlands, West Midlands
Panel: Abbvie Ltd, Alimera Sciences, Bayer Plc +11 more
- Contract value
- £689mceiling for the whole framework
- Annual run-rate
- —panel, not one supplier
- Term
- 1 Dec 2025 → 31 May 2027 · 1.4 yrs · up to 31 May 2029 with extensions
- Reference
ocds-h6vhtk-055064
- Ends · in 231 daysFramework re-letExtension option · up to 31 Jan 2030Panel · 21 suppliers
NHS National Framework for Generics Housekeeping Lot 1 - Oral Products
NHS England · Central government · North East England, North West England, Yorkshire and the Humber, East Midlands, West Midlands, East of England
Panel: ACCORD-UK LTD, Alissa Healthcare Research Limited, Brown and Burk UK Ltd +18 more
- Contract value
- £18mceiling for the whole framework
- Annual run-rate
- —panel, not one supplier
- Term
- 1 Feb 2026 → 31 May 2027 · 1.3 yrs · up to 31 Jan 2030 with extensions
- Reference
ocds-h6vhtk-058823
- Ends · in 231 daysFramework re-letExtension option · up to 31 May 2028Panel · 16 suppliers
Lot 1 - CM/PHG/23/5699/01 Oral (plus non-parenteral) products
NHS England · Central government · North East England, North West England, Yorkshire and the Humber, East Midlands, West Midlands, East of England
Panel: Amarox Limited, Brown and Burk UK Ltd, Celix Pharma Ltd. +13 more
- Contract value
- £18mceiling for the whole framework
- Annual run-rate
- —panel, not one supplier
- Term
- 1 Jun 2026 → 31 May 2027 · 11 months · up to 31 May 2028 with extensions
- Reference
ocds-h6vhtk-05193a
- Ends · in 231 daysFramework re-letPanel · 29 suppliers
Lot 1.2 - Technology Enabled Care (Telecare) services
ESPO · Nationwide (UK)
Panel: Alcove Limited, Appello Smart Living Solutions, BDS (Northern) Ltd t/a BDS Recruitment +26 more
- Contract value
- £8.8mceiling for the whole framework
- Annual run-rate
- —panel, not one supplier
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-04c625
- Ends · in 231 daysFramework re-letPanel · 22 suppliers
Lot 1.1 - Technology Enabled Care (Telecare) products and associated services
ESPO · Nationwide (UK)
Panel: Access UK Ltd, Alcove Limited, Alertacall Limited +19 more
- Contract value
- £5.6mceiling for the whole framework
- Annual run-rate
- —panel, not one supplier
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-04c625
- Ends · in 231 daysFramework re-letPanel · 13 suppliers
Lot 2.1 - Telehealth products and associated services
ESPO · Nationwide (UK)
Panel: Abilia Ltd, Baywater Healthcare UK Limited, Broomwell Healthwatch Limited +10 more
- Contract value
- £800kceiling for the whole framework
- Annual run-rate
- —panel, not one supplier
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-04c625
- Ends · in 231 daysFramework re-letPanel · 16 suppliers
Lot 2.2 - Telehealth services
ESPO · Nationwide (UK)
Panel: Baywater Healthcare UK Limited, Broomwell Healthwatch Limited, EVONDOS OY +13 more
- Contract value
- £800kceiling for the whole framework
- Annual run-rate
- —panel, not one supplier
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-04c625
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Milpharm Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Roma Pharmaceuticals Limited
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Perennial Pharma Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Consilient Health Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Pfizer Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Rosemont Pharmaceuticals Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: GLAXOSMITHKLINE UK LIMITED
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Aventis Pharma Ltd Trading As Sanofi
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Sandoz
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Flynn Pharma Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Dr Reddy's Laboratories (UK) Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Kent Pharma Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Glenmark Pharmaceuticals Europe Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Esteve Pharmaceuticals Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Healthcare Pharma Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Ranbaxy (UK) Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: CST Pharma Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
- Ends · in 231 daysFramework re-let
Wave 14c - Orals (plus non-parenteral) Products (all regions)
NHS England · NHS & health · Nationwide (UK)
Incumbent: Teva UK Ltd
- Contract value
- £1ceiling for the whole framework
- Annual run-rate
- —ceiling, not a run-rate
- Term
- Ends 31 May 2027 · start not published
- Reference
ocds-h6vhtk-040d4d
How to read the radar
- End date is the contract period end the buyer published on Find a Tender. Contracts without an end date are not on the radar.
- Extension option means the notice publishes a renewal or option clause; the buyer may extend instead of retendering. Hide them to see contracts that must be re-procured.
- Incumbent is the canonical supplier on the award behind the contract. A panel (several suppliers on one award) is shown as a panel — no single incumbent is invented.
- Annual run-rate = published GBP value ÷ published term, only for a single supplier, a term of six months or more and a plain contract (not a framework or DPS ceiling).
- Counts are exact from the nightly projection when you filter by horizon and sector only; any other filter shows a bounded total — exact up to 1,000 contracts, an honest “1,000+” floor above that.